Infliximab for Injection
Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.
The first infliximab biosimilar marketed in China
Infliximab for Injection (Reminton), a recombinant anti-TNF-alpha chimeric monoclonal antibody, was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Remin_x005f ton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.
Indications:
Crohn's disease in adults and children over 6 years of age, stulizing Crohn's disease,
ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, and psoriasis.
Recommended reading
Related products
-
1408Wh Power Station with jump starter
Contact UsUnleash power with our 1408Wh Power Station & Jump Starter.
-
7000A 12V&24V Jump Starter for Truck Starting in -40C
Contact Us（*For Jump Starter ODM/OEM Solutions, secure your exclusive quotation now!）
-
Durable moving bed carpet
Contact UsThe vacuum cleaner mobile test bench, model ZYXCQ-8A, is an intelligent aging test bench designed and implemented based on the complete machine testing requirements of the IEC-60312 standard.
-
Gel & Clot Activator Tube
Contact UsGel and clot activator tube is used for blood serum biochemistry, immunology and drug testing, etc.
Reviews
There are no reviews yet.